Developer docs
API playgroundTry for free, no card

Search company profiles

Laminar

Full company profile

uuid000bxgd

Namestring
Laminar
Legal namestring
Laminar Inc.
Websiteurl
laminarlaa.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Laminar Inc. is a medical device company founded in 2019 and headquartered in Santa Rosa, California, focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation. The company's core offering is an investigational LAAX technology for structural-heart and left-atrial-appendage management — a device-based approach to a structural cardiac intervention. At acquisition, Laminar operated with 11-50 employees and had no commercial product disclosed in available sources. Early-stage funding came from Sante Ventures. The company's underlying business model centered on developing and eventually commercializing an LAA elimination device through the regulated FDA medical-device pathway.

In November 2023, Johnson & Johnson MedTech acquired Laminar Inc. for $400 million, integrating it as a wholly-owned subsidiary within J&J's cardiovascular division. The acquisition was part of J&J MedTech's broader cardiovascular strategy, which included over $30 billion in cardiovascular deals spanning Laminar, Shockwave Medical, and V-Wave. Post-acquisition, Laminar's technology gains access to J&J MedTech's global clinical, regulatory, and distribution infrastructure. Pricing, go-to-market details, and current commercial revenue are not publicly disclosed. (Note: Several data sources reference a separate "Laminar" — a physical AI / spectral-sensor company serving CPG manufacturers including Coca-Cola, AB InBev, Danone, and Unilever. This appears to be a distinct entity unrelated to the medical-device Laminar Inc. under analysis.)

Short descriptiontext

Laminar Inc. is a medical device company developing investigational LAAX technology to eliminate the left atrial appendage in non-valvular atrial fibrillation patients. Founded in 2019 in Santa Rosa, California, it was acquired by Johnson & Johnson MedTech for $400 million in November 2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSanta Rosa, United States
HQ citystring
Santa Rosa
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cardiac medical devices, left atrial appendage closure, atrial fibrillation treatment, structural heart devices, cardiovascular implants
Industry1 code
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
Product category
Cardiac Medical Devices
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Laminar Inc. is a medical device company developing investigational LAAX technology for eliminating the left atrial appendage in patients with non-valvular atrial fibrillation. The company's product targets left atrial appendage closure as a structural-heart intervention. Laminar was acquired by Johnson & Johnson MedTech in November 2023 for $400 million.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Laminar is a physical AI solutions provider that offers a self-driving manufacturing platform for the consumer packaged goods (CPG) industry. The company provides spectral sensors and ML models that enable autonomous factory operations. The company's innovations transform factory operations and have been deployed across six continents for major clients including Coca-Cola, AB InBev, Danone, and Unilever.

Product and service1 record
1LAAX (investigational left atrial appendage closure device)
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medtronic is a broad cardiovascular incumbent with cardiac surgery and structural-heart offerings relevant to LAA management; it represents a potential alternative acquirer or competitor to Laminar's LAAX positioning.

TypeBroad incumbent
Description

Edwards Lifesciences is a structural-heart leader (surgical and transcatheter valves) whose portfolio and physician relationships are directly relevant to the LAA closure category in which Laminar operates.

TypeDirect peer
Description

Boston Scientific markets the Watchman family of left atrial appendage closure devices, the dominant direct competitor to Laminar's LAAX technology in the structural-heart stroke-prevention space for AF patients.

TypeOthers
Description

J&J MedTech is the parent entity that acquired Laminar and now houses the LAAX program; it is included as the structural integration vehicle and primary commercial channel through which the technology's value will be realized.

TypeEmerging player
Description

Conformal Medical is an early-to-mid stage developer of a next-generation LAA closure device, making it an emerging direct competitor to Laminar's LAAX in the structural-heart stroke-prevention space.

TypeEmerging player
Description

Append Medical is developing a transcatheter LAA exclusion technology targeting the same non-valvular AF stroke-prevention patient population as Laminar, representing an emerging peer in the investigational LAA closure category.

TypeEmerging player
Description

CardioFocus is an early-stage player in interventional cardiac technologies, including AF-related ablation and structural interventions, with partial overlap to Laminar's structural-heart AF portfolio.

TypeEmerging player
Description

SentreHEART developed LARIAT, a percutaneous LAA ligation system, positioning it as an emerging or niche peer to Laminar in LAA elimination approaches for AF-related stroke prevention.

9Abbott
TypeBroad incumbent
Description

Abbott is a diversified cardiovascular incumbent with structural-heart and electrophysiology franchises that overlap with Laminar's LAA closure and AF stroke-prevention focus, and could expand into LAA closure as a competitor or consolidator.

TypeDirect peer
Description

AtriCure is a structural-heart company developing left atrial appendage management solutions, including the AtriClip surgical LAA exclusion device, making it a direct comparator in the LAA elimination category that Laminar targets.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Laminar

Cardiac Medical Deviceslaminarlaa.com

Laminar Inc. is a medical device company developing investigational LAAX technology to eliminate the left atrial appendage in non-valvular atrial fibrillation patients. Founded in 2019 in Santa Rosa, California, it was acquired by Johnson & Johnson MedTech for $400 million in November 2023.

What Laminar does

Laminar Inc. is a medical device company founded in 2019 and headquartered in Santa Rosa, California, focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation. The company's core offering is an investigational LAAX technology for structural-heart and left-atrial-appendage management — a device-based approach to a structural cardiac intervention. At acquisition, Laminar operated with 11-50 employees and had no commercial product disclosed in available sources. Early-stage funding came from Sante Ventures. The company's underlying business model centered on developing and eventually commercializing an LAA elimination device through the regulated FDA medical-device pathway.

In November 2023, Johnson & Johnson MedTech acquired Laminar Inc. for $400 million, integrating it as a wholly-owned subsidiary within J&J's cardiovascular division. The acquisition was part of J&J MedTech's broader cardiovascular strategy, which included over $30 billion in cardiovascular deals spanning Laminar, Shockwave Medical, and V-Wave. Post-acquisition, Laminar's technology gains access to J&J MedTech's global clinical, regulatory, and distribution infrastructure. Pricing, go-to-market details, and current commercial revenue are not publicly disclosed. (Note: Several data sources reference a separate "Laminar" — a physical AI / spectral-sensor company serving CPG manufacturers including Coca-Cola, AB InBev, Danone, and Unilever. This appears to be a distinct entity unrelated to the medical-device Laminar Inc. under analysis.)

Laminar firmographics

Firmographics
Name
Laminar
Legal name
Laminar Inc.
Website
https://laminarlaa.com
Company type
Private
Founded year
2019
Operating status
Acquired
Headcount range
11–50 employees
Short description
Laminar Inc. is a medical device company developing investigational LAAX technology to eliminate the left atrial appendage in non-valvular atrial fibrillation patients. Founded in 2019 in Santa Rosa, California, it was acquired by Johnson & Johnson MedTech for $400 million in November 2023.
Ownership category
akta.pro rank

Laminar industry classification

Industry
Product category
Cardiac Medical Devices
akta.pro industry
PRIMARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cardiac medical devices
  • Left atrial appendage closure
  • Atrial fibrillation treatment
  • Structural heart devices
  • Cardiovascular implants

Where Laminar is headquartered

Location

Headquarters

HQ city
Santa Rosa
HQ country
United States
HQ region
North America

Markets served

Laminar business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Laminar product offering

Product offering

Core offering

Laminar Inc. is a medical device company developing investigational LAAX technology for eliminating the left atrial appendage in patients with non-valvular atrial fibrillation. The company's product targets left atrial appendage closure as a structural-heart intervention. Laminar was acquired by Johnson & Johnson MedTech in November 2023 for $400 million.

Product overview

Laminar is a physical AI solutions provider that offers a self-driving manufacturing platform for the consumer packaged goods (CPG) industry. The company provides spectral sensors and ML models that enable autonomous factory operations. The company's innovations transform factory operations and have been deployed across six continents for major clients including Coca-Cola, AB InBev, Danone, and Unilever.

Differentiator

Problem solved

Functional benefit

Products and services

  • LAAX (investigational left atrial appendage closure device)

Companies that use Laminar

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Laminar technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Laminar partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Laminar competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Medtronic is a broad cardiovascular incumbent with cardiac surgery and structural-heart offerings relevant to LAA management; it represents a potential alternative acquirer or competitor to Laminar's LAAX positioning.
  • Edwards Lifesciences: Edwards Lifesciences is a structural-heart leader (surgical and transcatheter valves) whose portfolio and physician relationships are directly relevant to the LAA closure category in which Laminar operates.
  • Abbott: Abbott is a diversified cardiovascular incumbent with structural-heart and electrophysiology franchises that overlap with Laminar's LAA closure and AF stroke-prevention focus, and could expand into LAA closure as a competitor or consolidator.

Direct peers

  • Boston Scientific: Boston Scientific markets the Watchman family of left atrial appendage closure devices, the dominant direct competitor to Laminar's LAAX technology in the structural-heart stroke-prevention space for AF patients.
  • AtriCure: AtriCure is a structural-heart company developing left atrial appendage management solutions, including the AtriClip surgical LAA exclusion device, making it a direct comparator in the LAA elimination category that Laminar targets.

Others

  • Johnson & Johnson MedTech: J&J MedTech is the parent entity that acquired Laminar and now houses the LAAX program; it is included as the structural integration vehicle and primary commercial channel through which the technology's value will be realized.

Emerging players

  • Conformal Medical: Conformal Medical is an early-to-mid stage developer of a next-generation LAA closure device, making it an emerging direct competitor to Laminar's LAAX in the structural-heart stroke-prevention space.
  • Append Medical: Append Medical is developing a transcatheter LAA exclusion technology targeting the same non-valvular AF stroke-prevention patient population as Laminar, representing an emerging peer in the investigational LAA closure category.
  • CardioFocus: CardioFocus is an early-stage player in interventional cardiac technologies, including AF-related ablation and structural interventions, with partial overlap to Laminar's structural-heart AF portfolio.
  • SentreHEART: SentreHEART developed LARIAT, a percutaneous LAA ligation system, positioning it as an emerging or niche peer to Laminar in LAA elimination approaches for AF-related stroke prevention.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Laminar social profiles

Digital presence

Laminar financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Laminar leadership team

Management profile

Number of profiles

Laminar funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Laminar M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laminar

What does Laminar do?

Laminar Inc. is a medical device company developing investigational LAAX technology for eliminating the left atrial appendage in patients with non-valvular atrial fibrillation. The company's product targets left atrial appendage closure as a structural-heart intervention. Laminar was acquired by Johnson & Johnson MedTech in November 2023 for $400 million.

Is Laminar a public or private company?

Laminar is a private company. It is classified as corporate owned and is currently acquired.

When was Laminar founded?

Laminar was founded in 2019. It employs 11 to 50 people.

Where is Laminar based?

Laminar is headquartered in Santa Rosa, United States, in the North America region.

Who are Laminar's main competitors?

Broad incumbents on record are Medtronic, Edwards Lifesciences and Abbott. Direct peers are Boston Scientific and AtriCure. Johnson & Johnson MedTech is listed as an others. Emerging players are Conformal Medical, Append Medical, CardioFocus and SentreHEART.

Does Laminar have an API?

No public API is recorded for Laminar.

What industry is Laminar in?

Laminar's product category is Cardiac Medical Devices. Its primary akta.pro industry code is HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comOcclusion Devices Market Overview, Key Trends, and Top Player AnalysisThe occlusion devices market is projected to reach $6.54 billion by 2030, growing at a compound annual growth rate of 9.2%, driven by rising neurological disorders, increased minimally invasive surgeries, and favorable reimbursement frameworks. In November 2023, Amring Pharmaceuticals Inc. acquired Laminar Inc. for an undisclosed sum, combining Nordic Pharma's expertise with Visant Medical's FDA-cleared LACRIFILL canalicular occlusive device for dry eye treatment. In July 2025, Embolx launched the Sniper G3 Balloon Occlusion Microcatheter, featuring a 24-month shelf life and improved trackability for targeted embolization procedures.openPR.comCompetitive Landscape: Leading Companies and New Entrants in the Implantable Cardiac Devices MarketThe implantable cardiac devices market is projected to reach $20.33 billion by 2030, growing at a compound annual growth rate of 8.8%, driven by rising demand for remote patient monitoring, minimally invasive procedures, and digital healthcare integration. In November 2023, Johnson & Johnson MedTech acquired Laminar Inc. for $400 million to strengthen its structural-heart and left-atrial-appendage management portfolio, adding Laminar's investigational LAAX technology. In October 2023, MicroPort CRM (France) launched its ULYS implantable cardioverter defibrillator and INVICTA defibrillation leads in Japan, reporting a 100% implantation success rate and 97.4% complication-free rate in clinical trials.openPR.comMarket Driver Insights: The Impact of Recent Advancements on the Atrial Fibrillation Devices MarketThe Business Research Company released a market report projecting the atrial fibrillation devices market to reach $14.77 billion by 2030, driven by technological innovations and increased demand for minimally invasive treatments. The article highlights key industry developments, including Johnson & Johnson's acquisition of Laminar Inc. and GE HealthCare's launch of the CardioVisio clinical decision support platform.Market ScoopAlopecia MarketThe global alopecia market is projected to grow from US$9.1 billion in 2023 to US$24.7 billion by 2033, representing a compound annual growth rate of 10.5%, driven by increasing prevalence of hair loss, technological advancements in treatments, and rising cosmetic awareness. North America leads the market with a 36.2% share, while key players including Sun Pharmaceuticals, Johnson & Johnson, Merck, and Dr. Reddy's Laboratories compete across pharmaceutical and device segments. Notable recent strategic moves include Sun Pharmaceuticals' $576 million acquisition of Concert Pharmaceuticals for its alopecia areata drug deuruxolitinib and Johnson & Johnson's $400 million acquisition of Laminar, reflecting active consolidation in the sector.BenzingaJ&J Braces For Q1 Earnings With Bearish Charts And Patent Cliffs In Play - Johnson & Johnson (NYSE:JNJ)Johnson & Johnson is set to report first-quarter earnings on April 16, with Wall Street expecting $2.64 in EPS and $21.4 billion in revenues, as the company's stock has declined 9.54% over the past year and 5.88% year-to-date. Technical analysis indicates a strongly bearish trend with the share price below key moving averages and an RSI suggesting the stock is deeply oversold at 26.32. The company faces patent cliffs threatening billions in revenue but is countering through acquisitions including Shockwave Medical for $12.5 billion, along with Abiomed and Laminar to bolster its MedTech segment.BenzingaJohnson & Johnson's Strategic Forecast: Targets 5%-6% Operational Sales Growth For FY24 - Johnson & JohnsJohnson & Johnson has issued its FY24 guidance projecting operational sales growth of 5%-6% and adjusted operational EPS of $10.55-$10.75, representing 7.3% growth at midpoint. The company expects the previously announced Laminar acquisition to have a dilutive impact of approximately $0.15 per share on adjusted EPS. J&J forecasts strong demand for key drugs including Darzalex, Carvykti, and Stelara, with its Innovative Medicine pipeline targeting 5%-7% operational sales growth from 2025-2030.PR NewswireLaminar, Inc. Acquired by Johnson & Johnson Medtech for $400 Million Upfront with Additional Clinical and Regulatory Milestone Payments in 2024 and BeyondJohnson & Johnson Medtech has acquired Laminar, Inc. for an upfront payment of $400 million plus additional clinical and regulatory milestone payments. The acquisition integrates Laminar's innovative rotational motion device for treating atrial fibrillation into Johnson & Johnson's Biosense Webster division. Santé Ventures, the sole venture capital investor in Laminar, facilitated the deal which follows recent FDA approval for a U.S. pivotal study.MassDeviceJohnson & Johnson MedTech enters LAA device space with acquisition of LaminarJohnson & Johnson MedTech completed the acquisition of Laminar, a left atrial appendage device maker, for a $400 million upfront payment plus potential milestone payments. This move adds J&J to the competitive LAA device market alongside established players like Abbott and Boston Scientific, introducing Laminar's unique rotational motion technology. Consequently, Johnson & Johnson adjusted its 2023 adjusted EPS forecast downward by approximately 17 cents due to an in-process R&D charge associated with the deal.Business Wire BlogJohnson & Johnson MedTech Acquires Laminar, Inc.Johnson & Johnson MedTech has completed the acquisition of Laminar, Inc., a medical device company focused on treating non-valvular atrial fibrillation, for an upfront payment of $400 million plus potential milestone payments. Laminar’s investigational device, which uses rotational motion to eliminate the left atrial appendage, will join Biosense Webster to expand J&J's portfolio in the high-growth cardiac arrhythmia market. The transaction is expected to reduce Johnson & Johnson's adjusted EPS by approximately $0.17 in fiscal year 2023 due to an in-process research and development charge.BioSpaceJohnson & Johnson MedTech Acquires Laminar, Inc.Johnson & Johnson MedTech completed the acquisition of Laminar, Inc., a medical device company specializing in left atrial appendage elimination for stroke prevention in atrial fibrillation patients, for an upfront payment of $400 million. Laminar will join Biosense Webster to expand its portfolio in the high-growth cardiac arrhythmia market. The transaction is expected to reduce Johnson & Johnson's Adjusted EPS by approximately $0.17 in fiscal year 2023 and $0.15 in 2024 due to in-process research and development charges.